Novavax
NVAX
$9.99
-9.26%
Novavax Inc. is a clinical and commercial-stage biotechnology company that develops protein-based vaccines and adjuvanted vaccine candidates for infectious diseases, including COVID-19, influenza, and combination respiratory vaccines, operating within the global vaccines and biotechnology industry. The company is a niche challenger in a market dominated by mRNA and traditional vaccine giants, distinguished by its Matrix-M adjuvant platform and its strategic pivot toward licensing and partnership-driven monetization rather than standalone commercial infrastructure. The current investor narrative centers on the durability of that pivot: a landmark licensing and royalty arrangement has transformed Novavax from a cash-burning commercial-stage vaccine maker into a leaner, royalty-generating entity, and recent quarterly results showing sales that more than doubled analyst expectations have fueled debate over whether the company can sustain profitability as COVID-related revenue fades. Attention is further amplified by competitive developments at Moderna, whose cancer-vaccine progress keeps the broader vaccine sector in the spotlight, while Novavax's own story hinges on pipeline execution, cost discipline, and the trajectory of its remaining product revenue.…
NVAX
Novavax
$9.99
Related headlines
Investment Opinion: Should I buy NVAX Today?
Rating: Hold. The core thesis is that Novavax is a speculative turnaround story where the high-margin royalty model and low PS multiple (0.97x) offer potential upside, but the severe revenue decline (-76.3% YoY) and cash burn (-$74.14 million in Q2 2026) create binary risk. The analyst consensus rating of 'buy' with an average target of $14.22 (+26.3% upside) suggests the sell-side sees value, but the wide target range ($7.00-$25.00) signals low conviction.\n\nSupporting evidence includes the 93.67% trailing gross margin, which highlights the potential profitability of the royalty model if revenue scales; the PS ratio of 0.97x, which is a 75-85% discount to biotech sector norms; the current ratio of 2.13, indicating adequate short-term liquidity; and the strong relative strength (+45.99 percentage points YTD vs. the S&P 500), reflecting improving sentiment. However, these positives are offset by negative free cash flow, negative equity, and a forward PE of -68.70x, indicating expected losses.\n\nThe biggest risks are cash runway (2-3 quarters at current burn), revenue concentration in lumpy licensing payments, and competitive pressure from Moderna and other vaccine giants. The rating would upgrade to Buy if the company demonstrates two consecutive quarters of positive free cash flow or secures a major new royalty-generating partnership; it would downgrade to Sell if cash falls below $100 million or revenue declines another 50% YoY. Relative to its history and peers, NVAX is undervalued on a PS basis but fairly valued given its distressed fundamentals—the low multiple is compensation for risk, not a margin of safety.
Sign up to view all
NVAX 12-Month Price Forecast
The risk/reward is balanced but highly uncertain. The low PS multiple and high gross margin suggest the market is overly punitive, but the cash burn and revenue collapse are real near-term threats. The analyst consensus is moderately bullish, but the wide target range reflects low conviction. I would upgrade to bullish if the company secures a major new partnership or shows positive free cash flow, and downgrade to bearish if cash falls below $100 million or revenue declines another 50%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Novavax's 12-month outlook, with a consensus price target around $14.22 and implied upside of +42.4% versus the current price.
Average Target
$14.22
0 analysts
Implied Upside
+42.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$7 - $25
Analyst target range
Nine analysts cover Novavax, and the consensus recommendation is "buy" with a mean rating of 2.33 on a scale where lower is more bullish, indicating a moderately positive but not unanimous stance. The average target price of $14.22 implies approximately +26.3% upside from the current $11.26, a meaningful gap that suggests the sell-side sees the recent pullback as an opportunity rather than a trend reversal. The bullish tilt is notable given the stock's 2.44 beta and negative forward earnings, implying analysts are underwriting pipeline and royalty catalysts rather than near-term profitability.
The target range is extremely wide, from a low of $7.00 (roughly -37.8% downside) to a high of $25.00 (about +122% upside), a spread of more than 3.5x that signals high uncertainty and low conviction in any single outcome. The high target likely assumes successful pipeline readouts, expanding royalty revenue, and multiple expansion toward sector norms, while the low target prices in continued revenue erosion, cash burn, and competitive pressure from larger vaccine players. Institutional ratings show a split house: BTIG, HC Wainwright, and B. Riley maintain Buy ratings, TD Cowen is Hold, and JP Morgan and B of A carry Underweight/Underperform stances, with B. of A. notably downgrading from Neutral to Underperform in August 2025; this polarization, combined with the wide target spread, means investors should weight the dispersion of views as heavily as the consensus itself.
Bulls vs Bears: NVAX Investment Factors
The bear case currently has stronger evidence: revenue is collapsing (-76.3% YoY), cash burn is accelerating (-$74.14 million in Q2 2026), and the company has negative equity. However, the bull case rests on a high-margin royalty model (93.67% trailing gross margin), a low PS multiple (0.97x), and analyst targets implying 26% upside. The single most important tension is whether the licensing and royalty pipeline can generate recurring revenue before cash reserves are depleted—a binary outcome that will determine whether NVAX is a value opportunity or a value trap.
Bullish
- Analyst consensus sees 26% upside: Nine analysts rate NVAX a 'buy' with a mean rating of 2.33 and an average target price of $14.22, implying +26.3% upside from the current $11.26. Even the lowest target of $7.00 is only -37.8% below, while the high target of $25.00 offers +122% upside, suggesting the sell-side is underwriting pipeline and royalty catalysts.
- High-margin royalty model emerging: Trailing gross margin is 93.67% and Q2 2026 gross margin was 74.87%, reflecting the economics of vaccine licensing and royalties. If royalty streams scale, the incremental revenue would drop through at very high margins, potentially transforming profitability.
- Strong relative price momentum: NVAX is up 57.92% YTD and 37.15% over three months, outpacing the S&P 500 by 45.99 and 34.46 percentage points respectively. The 1-month gain of 20.43% exceeds the 1-year gain of 32.78%, indicating accelerating momentum.
- Liquidity cushion supports runway: The current ratio of 2.13 and quick ratio of 2.30, with $197.06 million in cash at Q2 2026, provide adequate short-term liquidity. This gives management time to execute on partnerships and pipeline milestones without immediate financing pressure.
Bearish
- Revenue collapsing 76% year-over-year: Q2 2026 revenue of $56.70 million represents a -76.3% decline from $239.24 million in Q2 2025, and sequential revenue has fallen from $666.66 million in Q1 2025 to $56.70 million. The licensing windfall is not recurring, and the remaining revenue base is small and lumpy.
- Cash burn and negative free cash flow: Free cash flow is -$43.59 million on a trailing-twelve-month basis and -$74.14 million in Q2 2026 alone, with operating cash flow of -$75.41 million for the quarter. Cash declined from $256.05 million at year-end 2025 to $197.06 million at Q2 2026, implying a runway of roughly 2-3 quarters at the current burn rate.
- Negative equity and extreme ROE: Debt-to-equity is -1.95 and ROE is -344.65%, reflecting a negative equity position from accumulated losses. This makes traditional leverage metrics unreliable and highlights the company's dependence on external financing or asset monetization.
- Operating losses despite high gross margin: Q2 2026 operating margin was -96.84% with a net loss of $53.39 million, as R&D spending of $70.69 million and total operating expenses of $97.36 million overwhelmed the shrunken revenue base. The gap between gross and operating margins is the central issue.
NVAX Technical Analysis
Novavax is in a sustained recovery uptrend, with the stock up 32.78% over the past year and 57.92% year-to-date, a sharp reversal from the depressed levels that characterized its post-pandemic collapse. At the current price of $11.26, the stock sits at roughly 70% of its 52-week range (low of $6.20 to high of $13.39), positioning it in the upper half of the band but still about 16% below the high, which suggests constructive momentum without the overextension that typically accompanies a fresh breakout. The 52-week low of $6.20 was set earlier in the period, and the higher-low structure since then supports the case that the downtrend has been broken.
Short-term momentum is strongly positive and accelerating: the stock is up 20.43% over the past month and 37.15% over three months, both dramatically outpacing the S&P 500's 1.22% and 2.69% respective gains, producing relative strength readings of +19.21 and +34.46 percentage points. This is not a divergence but a confirmation of the longer-term trend, with the 1-month gain exceeding the 1-year gain, indicating that the pace of appreciation has quickened rather than faded. However, the most recent session shows a sharp -12.17% single-day drop from a previous close of $12.82 to $11.26 on elevated volume of roughly 9.87 million shares, a warning sign that the rally may be hitting resistance or that profit-taking has begun; the short ratio of 8.08 days to cover also signals meaningful bearish positioning that can amplify volatility in both directions.
Key technical levels are well defined: support rests at the 52-week low of $6.20, with intermediate support likely in the $9.00-$9.50 zone that contained prices through mid-2026, while resistance sits at the 52-week high of $13.39, which the stock approached but failed to breach in mid-October. A decisive breakout above $13.39 would confirm the multi-year base and likely invite momentum buyers, whereas a breakdown below $9.00 would undermine the recovery thesis and reopen the $6.20 low. With a beta of 2.435, Novavax is roughly 2.4 times as volatile as the market, and its maximum drawdown of -34.87% over the period underscores that position sizing must account for violent swings; risk management, not conviction alone, determines outcomes in a name like this.
Beta
2.44
2.44x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$6-$13
Price range past year
Annual Return
+18.1%
Cumulative gain past year
| Period | NVAX Return | S&P 500 |
|---|---|---|
| 1m | -7.8% | -1.2% |
| 3m | +33.9% | +3.4% |
| 6m | +21.5% | +7.0% |
| 1y | +18.1% | +14.4% |
| ytd | +40.1% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVAX Fundamental Analysis
Novavax's revenue trajectory is highly volatile and currently contracting sharply on a year-over-year basis: Q2 2026 revenue of $56.70 million represents a -76.3% decline versus the prior-year quarter's $239.24 million, a comparison distorted by the massive $666.66 million in Q1 2025 revenue tied to a one-time licensing arrangement. Sequentially, revenue fell from $139.51 million in Q1 2026 and $147.14 million in Q4 2025, confirming that the licensing windfall is not recurring at scale; the segment data shows $37.84 million in licensing, royalties, and other revenue alongside just $0.68 million in royalties and other, highlighting dependence on lumpy partnership payments. The investment case therefore rests less on top-line growth and more on whether royalty streams and pipeline milestones can stabilize the revenue base, with consensus estimated revenue of $376.6 million for the forward period implying expectations of a rebound from the current run-rate.
Profitability is erratic and currently negative: Q2 2026 produced a net loss of $53.39 million and negative EBITDA of $39.87 million, a stark reversal from Q4 2025's $17.53 million net profit and Q1 2026's modest $9.49 million loss. Gross margin remains exceptionally high at 74.87% in Q2 2026 (and 93.67% on a trailing basis), consistent with the economics of vaccine licensing and royalty models, but operating margin of -96.84% in the quarter reveals that R&D spending of $70.69 million and total operating expenses of $97.36 million overwhelm the shrunken revenue base. The trailing net margin of 39.19% is an artifact of the prior licensing gains rather than current operations, and the gap between gross and operating margins is the central issue: the company must either grow revenue or cut its cost structure to convert its high-margin product economics into sustainable bottom-line results.
Balance sheet health is mixed but manageable: the current ratio of 2.13 and quick ratio of 2.30 indicate adequate short-term liquidity, with $197.06 million in cash at the end of Q2 2026, though that is down from $256.05 million at year-end 2025. Free cash flow is negative, with -$43.59 million on a trailing-twelve-month basis and -$74.14 million in Q2 2026 alone, while operating cash flow was -$75.41 million for the quarter, meaning the company is burning cash and reliant on its existing reserves and investment portfolio rather than internal generation. The debt-to-equity ratio of -1.95 and ROE of -344.65% reflect a negative equity position, a legacy of accumulated losses that makes traditional leverage metrics unreliable; the company's survival depends on preserving its cash cushion and monetizing its pipeline and royalty assets before reserves are depleted.
Quarterly Revenue
$56698000.0B
2026-06
Revenue YoY Growth
-76.3%
YoY Comparison
Gross Margin
74.9%
Latest Quarter
Free Cash Flow
$-43592000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVAX Overvalued?
Because trailing net income is positive (EPS of $0.40, driven by licensing gains), the PE ratio is the appropriate primary metric, and the trailing PE of 2.47x is optically extremely cheap; however, this is misleading because the earnings base is non-recurring. The forward PE of -68.70x is negative, signaling that consensus expects a loss in the forward period, which makes the trailing PE essentially meaningless as a valuation anchor. In this situation, the price-to-sales ratio of 0.97x and EV/sales of 4.09x are more informative, and the wide gap between the two reflects the company's net cash position relative to its modest revenue base.
Against the biotechnology sector, where profitable vaccine and large-cap biotech peers typically trade at PS multiples of 4x-8x and unprofitable clinical-stage names often trade at 10x or more, Novavax's PS of 0.97x looks like a steep discount of roughly 75%-85% versus sector norms. That discount is partly justified: revenue is declining at a -76.3% year-over-year rate, free cash flow is negative at -$43.59 million, and the company has negative book value (PB of -8.52x), all of which argue for a distressed multiple. Yet the 93.67% trailing gross margin and the potential for high-margin royalty streams suggest the market may be overly punitive if the licensing pipeline delivers, making the discount a bet on execution rather than a straightforward value signal.
Historically, Novavax's PS ratio has swung violently, from 27.34x in Q2 2026's reported historical data and 19.98x in Q3 2025 down to 1.55x in Q1 2025 when licensing revenue spiked, illustrating how the multiple is distorted by revenue lumpiness rather than reflecting a stable valuation band. The current PS of 0.97x is near the low end of its multi-year range, which could indicate either a genuine value opportunity or persistent fundamental deterioration; given the negative forward earnings and cash burn, the market appears to be pricing in skepticism about revenue durability. Investors should treat the low multiple as compensation for risk rather than a margin of safety until recurring revenue and positive free cash flow are demonstrated.
PE
2.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~7x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
2.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe. Revenue is contracting at a -76.3% year-over-year rate, with Q2 2026 revenue of $56.70 million versus $239.24 million a year earlier, and the licensing windfall that boosted Q1 2025 revenue to $666.66 million is non-recurring. Free cash flow is negative at -$43.59 million TTM and -$74.14 million in Q2 2026 alone, while cash declined from $256.05 million at year-end 2025 to $197.06 million at Q2 2026—a burn rate that could exhaust reserves within 2-3 quarters without new financing or partnership inflows. The company also has negative equity (debt-to-equity of -1.95) and an ROE of -344.65%, making it dependent on external capital.\n\nMarket and competitive risks are amplified by NVAX's high beta of 2.435, meaning it is roughly 2.4 times as volatile as the market, and its maximum drawdown of -34.87% over the period. The stock trades at a PS of 0.97x, which is a steep discount to biotech peers, but that discount is justified by declining revenue and negative cash flow; if revenue fails to stabilize, the multiple could compress further. Competitive pressure from Moderna's mRNA cancer vaccine progress and larger vaccine players like Pfizer and GSK could limit Novavax's ability to win new contracts, while the short ratio of 8.08 days to cover indicates meaningful bearish positioning that can amplify downside moves.\n\nThe worst-case scenario involves a failed pipeline readout or loss of a major partnership, combined with continued cash burn, forcing a dilutive equity raise or asset sale at distressed prices. In this scenario, the stock could retest its 52-week low of $6.20, representing a -44.9% decline from the current $11.26, or fall to the analyst low target of $7.00 (-37.8%). A more severe outcome, such as a liquidity crisis, could push shares below $6.20 toward the $4-5 range, implying a loss of 55-65% from current levels.
FAQ
The most severe risk is liquidity: cash of $197.06 million at Q2 2026 is burning at -$74.14 million per quarter, implying a runway of 2-3 quarters without new financing. Second is revenue concentration in lumpy licensing payments, with Q2 2026 revenue down -76.3% YoY. Third is competitive pressure from Moderna and other vaccine giants, which could limit new contract wins. Fourth is high volatility (beta 2.435) and a short ratio of 8.08 days to cover, which can amplify downside moves.
The 12-month forecast is highly uncertain. Base case (50% probability) targets $11.26-$14.22, assuming revenue stabilizes and cash burn moderates. Bull case (25%) targets $14.22-$25.00 on pipeline success and new partnerships. Bear case (25%) targets $6.20-$7.00 if cash reserves deplete or a pipeline fails. The most likely scenario is the base case, but the wide range reflects binary outcomes. Key assumption: revenue meets consensus of $376.6 million.
On a PS basis, NVAX appears undervalued at 0.97x versus biotech peers at 4x-8x, but this discount is justified by negative free cash flow and declining revenue. The trailing PE of 2.47x is misleading due to non-recurring licensing gains, and the forward PE of -68.70x signals expected losses. The market is pricing in skepticism about revenue durability; the stock is fairly valued given the risk profile, with upside only if execution improves.
NVAX is a high-risk, high-reward speculative buy only for investors with a strong risk appetite. The analyst consensus target of $14.22 implies 26.3% upside, and the low PS of 0.97x suggests the market is pricing in significant pessimism. However, the -76.3% revenue decline and -$74.14 million quarterly cash burn mean the company could need financing within 2-3 quarters, risking dilution. A good buy for contrarian investors who believe in the royalty model and pipeline, but position sizing should be small.
NVAX is more suitable for short-term trading than long-term holding due to its binary risk profile and high volatility (beta 2.435). The stock's 57.92% YTD gain and 20.43% monthly gain show momentum, but the -12.17% single-day drop highlights reversal risk. Long-term investors would need to tolerate potential dilution and years of uncertain pipeline development. A minimum holding period of 12-18 months is suggested only for those with high risk tolerance, and positions should be sized to withstand a 50% drawdown.